Idiopathic triglyceride deposit cardiomyovasculopathy (TGCV).
Conditions
Interventions
CNT-01(500mg), Oral, 3/day, 8weeks
Placebo (control), Oral, 3/day, 8weeks
Sponsors
Osaka university hospital
Aichi medical university hosiptal Juntendo university hospital Chiba university hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have definite diagnosis of idiopathic TGCV. 2) BMIPP washout rate is less than 5% 3) Patients who walk for 6 minutes walking distance less than 400 m 4) Patients who got adequate explanation and understanding to participate in this trial and document consent by the individual 5) Patients whose age is over 20 years at the time of consent acquisition 6) Patients who can be taken orally
Exclusion criteria
Exclusion criteria: 1) Patients within 1 month of revascularization of coronary arteries 2) Patients with fasting serum capric acid concentration> 10 umol / L 3) Patients who had diet therapy containing medium chain fatty acid even once in the past 4) Patients with diabetic ketoacidosis 5) A pregnant patient, a pregnant woman or a lactating patient 6) Class IV patients with NYHA cardiac function classification 7) Patients with acute coronary syndrome 8) Patients with a history of drug addiction 9) Patients who are allergic to the ingredients of the CNT-01 10) Patients who are allergic to BMIPP or iodine 11) Patients with a history of clinically important drug allergic symptoms 12) Patients with severe liver dysfunction (Child-Pugh classifications B or C) 13) Patients who took part in other clinical trial studies within 3 months 14) Patients judged unsuitable for inclusion in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in 6-minute walking distance (m) 8 weeks after administration. | — |
Countries
Japan
Contacts
Public ContactDaisaku Nakatani
Osaka University Hospital Medical innovation
Outcome results
None listed